| 2026-11-02 Filed 2026-11-04 | NEWHALL CHARLES W III Director | J Other acquisition or disposition (describe transaction) Common Stock | Disposed (D) | 124,119 | 0 | — | 0 | Direct (D) | No | F1 - F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/26, Artemis Merger Sub Inc. merged with and into Supernus Pharmaceuticals, with Supernus Pharmaceuticals surviving as a wholly-owned subsidiary of Indivior. At the effective time, each outstanding share of Supernus Pharmaceuticals common stock was cancelled and automatically converted into the right to receive 1.5401 shares of Indivior common stock. In connection with the merger, Indivior changed its name to Supernus, Inc. The reporting person's shares of Supernus Pharmaceuticals common stock were disposed of, and the shares of Supernus, Inc. common stock received in exchange were acquired, pursuant to the merger. The reporting person received no cash consideration other than cash in lieu of a fractional share.
| Open filing 0001005544-26-000006 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | NEWHALL CHARLES W III Director | J Other acquisition or disposition (describe transaction) Derivative security: Restricted Stock Unit — underlying Common Stock (2,989) | Disposed (D) | 2,989 | 0 | — | 0 | Direct (D) | No | F2, F3, F4 - F2 Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
- F3 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
- F4 These restricted stock units will be settled in common stock upon vesting, which will occur on February 18, 2027.
| Open filing 0001005544-26-000006 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | NEWHALL CHARLES W III Director | J Other acquisition or disposition (describe transaction) Derivative security: Director Stock Option (Right to Buy) — underlying Common Stock (7,905) — exercise price 25.30 | Disposed (D) | 7,905 | 0 | — | 0 | Direct (D) | No | F3 - F3 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
| Open filing 0001005544-26-000006 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | NEWHALL CHARLES W III Director | J Other acquisition or disposition (describe transaction) Derivative security: Director Stock Option (Right to Buy) — underlying Common Stock (6,036) — exercise price 38.60 | Disposed (D) | 6,036 | 0 | — | 0 | Direct (D) | No | F3 - F3 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
| Open filing 0001005544-26-000006 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | NEWHALL CHARLES W III Director | J Other acquisition or disposition (describe transaction) Derivative security: Director Stock Option (Right to Buy) — underlying Common Stock (8,613) — exercise price 39.40 | Disposed (D) | 8,613 | 0 | — | 0 | Direct (D) | No | F3 - F3 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
| Open filing 0001005544-26-000006 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | NEWHALL CHARLES W III Director | J Other acquisition or disposition (describe transaction) Derivative security: Director Stock Option (Right to Buy) — underlying Common Stock (12,427) — exercise price 36.75 | Disposed (D) | 12,427 | 0 | — | 0 | Direct (D) | No | F3 - F3 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
| Open filing 0001005544-26-000006 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | NEWHALL CHARLES W III Director | J Other acquisition or disposition (describe transaction) Derivative security: Director Stock Option (Right to Buy) — underlying Common Stock (9,305) — exercise price 23.99 | Disposed (D) | 9,305 | 0 | — | 0 | Direct (D) | No | F3 - F3 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
| Open filing 0001005544-26-000006 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | NEWHALL CHARLES W III Director | J Other acquisition or disposition (describe transaction) Derivative security: Director Stock Option (Right to Buy) — underlying Common Stock (7,365) — exercise price 29.61 | Disposed (D) | 7,365 | 0 | — | 0 | Direct (D) | No | F3 - F3 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
| Open filing 0001005544-26-000006 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | NEWHALL CHARLES W III Director | J Other acquisition or disposition (describe transaction) Derivative security: Director Stock Option (Right to Buy) — underlying Common Stock (6,847) — exercise price 32.20 | Disposed (D) | 6,847 | 0 | — | 0 | Direct (D) | No | F3 - F3 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
| Open filing 0001005544-26-000006 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | NEWHALL CHARLES W III Director | J Other acquisition or disposition (describe transaction) Derivative security: Director Stock Option (Right to Buy) — underlying Common Stock (6,293) — exercise price 38.60 | Disposed (D) | 6,293 | 0 | — | 0 | Direct (D) | No | F3, F5 - F3 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
- F5 The option vests on February 23, 2024.
| Open filing 0001005544-26-000006 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | NEWHALL CHARLES W III Director | J Other acquisition or disposition (describe transaction) Derivative security: Director Stock Option (Right to Buy) — underlying Common Stock (8,252) — exercise price 27.94 | Disposed (D) | 8,252 | 0 | — | 0 | Direct (D) | No | F3, F6 - F3 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
- F6 The option vests on February 22, 2025.
| Open filing 0001005544-26-000006 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | NEWHALL CHARLES W III Director | J Other acquisition or disposition (describe transaction) Derivative security: Director Stock Option (Right to Buy) — underlying Common Stock (7,296) — exercise price 33.52 | Disposed (D) | 7,296 | 0 | — | 0 | Direct (D) | No | F3, F7 - F3 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
- F7 The option vests on February 19, 2026.
| Open filing 0001005544-26-000006 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | NEWHALL CHARLES W III Director | J Other acquisition or disposition (describe transaction) Derivative security: Director Stock Option (Right to Buy) — underlying Common Stock (4,977) — exercise price 50.20 | Disposed (D) | 4,977 | 0 | — | 0 | Direct (D) | No | F3, F8 - F3 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
- F8 Each option vests on February 18, 2027.
| Open filing 0001005544-26-000006 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | Sensenig Bethany Director | J Other acquisition or disposition (describe transaction) Derivative security: Director Stock Option (Right to Buy) — underlying Common Stock (24,153) — exercise price 30.22 | Disposed (D) | 24,153 | 0 | — | 0 | Direct (D) | No | F1, F2 - F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
- F2 The option vests in four equal annual installments beginning on August 17, 2024.
| Open filing 0001899935-26-000009 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | Sensenig Bethany Director | J Other acquisition or disposition (describe transaction) Derivative security: Director Stock Option (Right to Buy) — underlying Common Stock (8,252) — exercise price 27.94 | Disposed (D) | 8,252 | 0 | — | 0 | Direct (D) | No | F1, F3 - F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
- F3 The option vests on February 22, 2025.
| Open filing 0001899935-26-000009 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | Sensenig Bethany Director | J Other acquisition or disposition (describe transaction) Derivative security: Director Stock Option (Right to Buy) — underlying Common Stock (7,296) — exercise price 33.52 | Disposed (D) | 7,296 | 0 | — | 0 | Direct (D) | No | F1, F4 - F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
- F4 The option vests on February 19, 2026.
| Open filing 0001899935-26-000009 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | Sensenig Bethany Director | J Other acquisition or disposition (describe transaction) Derivative security: Director Stock Option (Right to Buy) — underlying Common Stock (4,977) — exercise price 50.20 | Disposed (D) | 4,977 | 0 | — | 0 | Direct (D) | No | F1, F5 - F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
- F5 Each option vests on February 18, 2027.
| Open filing 0001899935-26-000009 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | Sensenig Bethany Director | J Other acquisition or disposition (describe transaction) Derivative security: Restricted Stock Unit — underlying Common Stock (2,989) | Disposed (D) | 2,989 | 0 | — | 0 | Direct (D) | No | F6, F1, F7 - F6 Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
- F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
- F7 These restricted stock units will be settled in common stock upon vesting, which will occur on February 18, 2027.
| Open filing 0001899935-26-000009 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | Horich William Todd Officer: SVP, Commercial Operations | J Other acquisition or disposition (describe transaction) Derivative security: Restricted Stock Unit — underlying Common Stock (100,000) — exercise price 0 | Disposed (D) | 100,000 | 0 | — | 0 | Direct (D) | No | F1, F2 - F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
- F2 These restricted stock units (RSUs) are settled in common stock upon vesting, which occurs in five installments. 40% of the RSUs vest upon the closing of the merger-of-equals transaction between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. (the Closing). 15% of the RSUs vest upon the one-year anniversary of the Closing. 15% of the RSUs vest upon the two-year anniversary of the Closing. 15% of the RSUs vest upon the three-year anniversary of the Closing. 15% of the RSUs vest upon the four-year anniversary of the Closing.
| Open filing 0002117599-26-000009 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | Horich William Todd Officer: SVP, Commercial Operations | J Other acquisition or disposition (describe transaction) Derivative security: Performance Share Unit — underlying Common Stock (5,000) | Disposed (D) | 5,000 | 0 | — | 0 | Direct (D) | No | F3, F1, F4 - F3 Each performance share unit represents the right to receive one share of Supernus common stock upon vesting.
- F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
- F4 On February 19, 2025, the Reporting Person was awarded Performance Share Units with individual performance objectives and a defined performance period established on May 3, 2025.
| Open filing 0002117599-26-000009 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | Horich William Todd Officer: SVP, Commercial Operations | J Other acquisition or disposition (describe transaction) Derivative security: Performance Share Unit — underlying Common Stock (3,500) | Disposed (D) | 3,500 | 0 | — | 0 | Direct (D) | No | F3, F1, F5 - F3 Each performance share unit represents the right to receive one share of Supernus common stock upon vesting.
- F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
- F5 On February 18, 2026, the Reporting Person was awarded Performance Share Units with individual performance objectives and a defined performance period established on July 15, 2026.
| Open filing 0002117599-26-000009 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | Horich William Todd Officer: SVP, Commercial Operations | J Other acquisition or disposition (describe transaction) Derivative security: Restricted Stock Unit — underlying Common Stock (6,250) | Disposed (D) | 6,250 | 0 | — | 0 | Direct (D) | No | F6, F1, F7 - F6 Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
- F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
- F7 These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024.
| Open filing 0002117599-26-000009 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | Horich William Todd Officer: SVP, Commercial Operations | J Other acquisition or disposition (describe transaction) Derivative security: Restricted Stock Unit — underlying Common Stock (2,500) | Disposed (D) | 2,500 | 0 | — | 0 | Direct (D) | No | F6, F1, F8 - F6 Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
- F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
- F8 These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2025.
| Open filing 0002117599-26-000009 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | Horich William Todd Officer: SVP, Commercial Operations | J Other acquisition or disposition (describe transaction) Derivative security: Restricted Stock Unit — underlying Common Stock (3,375) | Disposed (D) | 3,375 | 0 | — | 0 | Direct (D) | No | F6, F1, F9 - F6 Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
- F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
- F9 These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 19, 2026.
| Open filing 0002117599-26-000009 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | Horich William Todd Officer: SVP, Commercial Operations | J Other acquisition or disposition (describe transaction) Derivative security: Restricted Stock Unit — underlying Common Stock (3,000) | Disposed (D) | 3,000 | 0 | — | 0 | Direct (D) | No | F6, F1, F10 - F6 Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
- F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
- F10 These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 18, 2027.
| Open filing 0002117599-26-000009 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | Horich William Todd Officer: SVP, Commercial Operations | J Other acquisition or disposition (describe transaction) Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock (13,000) — exercise price 39.40 | Disposed (D) | 13,000 | 0 | — | 0 | Direct (D) | No | F1, F11 - F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
- F11 The option vests in four equal annual installments beginning on February 14, 2019.
| Open filing 0002117599-26-000009 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | Horich William Todd Officer: SVP, Commercial Operations | J Other acquisition or disposition (describe transaction) Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock (14,000) — exercise price 36.75 | Disposed (D) | 14,000 | 0 | — | 0 | Direct (D) | No | F1, F12 - F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
- F12 The option vests in four equal annual installments beginning on February 22, 2020.
| Open filing 0002117599-26-000009 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | Horich William Todd Officer: SVP, Commercial Operations | J Other acquisition or disposition (describe transaction) Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock (17,000) — exercise price 29.61 | Disposed (D) | 17,000 | 0 | — | 0 | Direct (D) | No | F1, F13 - F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
- F13 The option vests in four equal annual installments beginning on February 19, 2022.
| Open filing 0002117599-26-000009 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | Horich William Todd Officer: SVP, Commercial Operations | J Other acquisition or disposition (describe transaction) Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock (18,000) — exercise price 32.20 | Disposed (D) | 18,000 | 0 | — | 0 | Direct (D) | No | F1, F14 - F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
- F14 The option vests in four equal annual installments beginning on February 22, 2023.
| Open filing 0002117599-26-000009 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | Horich William Todd Officer: SVP, Commercial Operations | J Other acquisition or disposition (describe transaction) Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock (20,000) — exercise price 38.60 | Disposed (D) | 20,000 | 0 | — | 0 | Direct (D) | No | F1, F15 - F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
- F15 The option vests in four equal annual installments beginning on February 23, 2024.
| Open filing 0002117599-26-000009 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | Horich William Todd Officer: SVP, Commercial Operations | J Other acquisition or disposition (describe transaction) Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock (25,000) — exercise price 27.94 | Disposed (D) | 25,000 | 0 | — | 0 | Direct (D) | No | F1, F16 - F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
- F16 The option vests in four equal annual installments beginning on February 22, 2025.
| Open filing 0002117599-26-000009 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | Horich William Todd Officer: SVP, Commercial Operations | J Other acquisition or disposition (describe transaction) Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock (20,000) — exercise price 33.52 | Disposed (D) | 20,000 | 0 | — | 0 | Direct (D) | No | F1, F17 - F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
- F17 The option vests in four equal annual installments beginning on February 19, 2026.
| Open filing 0002117599-26-000009 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | Horich William Todd Officer: SVP, Commercial Operations | J Other acquisition or disposition (describe transaction) Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock (13,500) — exercise price 50.20 | Disposed (D) | 13,500 | 0 | — | 0 | Direct (D) | No | F1, F18 - F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
- F18 The option vests in four equal annual installments beginning on February 18, 2027.
| Open filing 0002117599-26-000009 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | Bhatt Padmanabh P. Officer: Sr. VP of IP, CSO | J Other acquisition or disposition (describe transaction) Common Stock | Disposed (D) | 18,637 | 0 | — | 0 | Direct (D) | No | F1 - F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/26, Artemis Merger Sub Inc. merged with and into Supernus Pharmaceuticals, with Supernus Pharmaceuticals surviving as a wholly-owned subsidiary of Indivior. At the effective time, each outstanding share of Supernus Pharmaceuticals common stock was cancelled and automatically converted into the right to receive 1.5401 shares of Indivior common stock. In connection with the merger, Indivior changed its name to Supernus, Inc. The reporting person's shares of Supernus Pharmaceuticals common stock were disposed of, and the shares of Supernus, Inc. common stock received in exchange were acquired, pursuant to the merger. The reporting person received no cash consideration other than cash in lieu of a fractional share.
| Open filing 0001539215-26-000014 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | Bhatt Padmanabh P. Officer: Sr. VP of IP, CSO | J Other acquisition or disposition (describe transaction) Derivative security: Performance Share Unit — underlying Common Stock (3,350) | Disposed (D) | 3,350 | 0 | — | 0 | Direct (D) | No | F2, F3, F4 - F2 Each performance share unit represents the right to receive one share of Supernus common stock upon vesting.
- F3 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
- F4 On February 22, 2024, the Reporting Person was awarded Performance Share Units with individual performance objectives and a defined performance period established on June 24, 2024.
| Open filing 0001539215-26-000014 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | Bhatt Padmanabh P. Officer: Sr. VP of IP, CSO | J Other acquisition or disposition (describe transaction) Derivative security: Performance Share Unit — underlying Common Stock (2,500) | Disposed (D) | 2,500 | 0 | — | 0 | Direct (D) | No | F2, F3, F5 - F2 Each performance share unit represents the right to receive one share of Supernus common stock upon vesting.
- F3 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
- F5 On February 19, 2025, the Reporting Person was awarded Performance Share Units with individual performance objectives and a defined performance period established on May 3, 2025.
| Open filing 0001539215-26-000014 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | Bhatt Padmanabh P. Officer: Sr. VP of IP, CSO | J Other acquisition or disposition (describe transaction) Derivative security: Performance Share Unit — underlying Common Stock (3,500) | Disposed (D) | 3,500 | 0 | — | 0 | Direct (D) | No | F2, F3, F6 - F2 Each performance share unit represents the right to receive one share of Supernus common stock upon vesting.
- F3 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
- F6 On February 18, 2026, the Reporting Person was awarded Performance Share Units with individual performance objectives and a defined performance period established on July 15, 2026.
| Open filing 0001539215-26-000014 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | Bhatt Padmanabh P. Officer: Sr. VP of IP, CSO | J Other acquisition or disposition (describe transaction) Derivative security: Restricted Stock Unit — underlying Common Stock (100,000) — exercise price 0 | Disposed (D) | 100,000 | 0 | — | 0 | Direct (D) | No | F3, F7 - F3 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
- F7 These restricted stock units (RSUs) are settled in common stock upon vesting, which occurs in four installments. 50% of the RSUs vest upon the closing of the merger-of-equals transaction between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. (the Closing). 15% of the RSUs vest upon the one-year anniversary of the Closing. 15% of the RSUs vest upon the two-year anniversary of the Closing. 20% of the RSUs vest upon the three-year anniversary of the Closing.
| Open filing 0001539215-26-000014 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | Bhatt Padmanabh P. Officer: Sr. VP of IP, CSO | J Other acquisition or disposition (describe transaction) Derivative security: Restricted Stock Unit — underlying Common Stock (1,250) | Disposed (D) | 1,250 | 0 | — | 0 | Direct (D) | No | F8, F3, F9 - F8 Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
- F3 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
- F9 These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024.
| Open filing 0001539215-26-000014 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | Bhatt Padmanabh P. Officer: Sr. VP of IP, CSO | J Other acquisition or disposition (describe transaction) Derivative security: Restricted Stock Unit — underlying Common Stock (2,500) | Disposed (D) | 2,500 | 0 | — | 0 | Direct (D) | No | F8, F3, F10 - F8 Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
- F3 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
- F10 These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2025.
| Open filing 0001539215-26-000014 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | Bhatt Padmanabh P. Officer: Sr. VP of IP, CSO | J Other acquisition or disposition (describe transaction) Derivative security: Restricted Stock Unit — underlying Common Stock (3,375) | Disposed (D) | 3,375 | 0 | — | 0 | Direct (D) | No | F8, F3, F11 - F8 Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
- F3 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
- F11 These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 19, 2026.
| Open filing 0001539215-26-000014 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | Bhatt Padmanabh P. Officer: Sr. VP of IP, CSO | J Other acquisition or disposition (describe transaction) Derivative security: Restricted Stock Unit — underlying Common Stock (3,000) | Disposed (D) | 3,000 | 0 | — | 0 | Direct (D) | No | F8, F3, F12 - F8 Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
- F3 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
- F12 These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 18, 2027.
| Open filing 0001539215-26-000014 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | Bhatt Padmanabh P. Officer: Sr. VP of IP, CSO | J Other acquisition or disposition (describe transaction) Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock (5,000) — exercise price 38.60 | Disposed (D) | 5,000 | 0 | — | 0 | Direct (D) | No | F3, F13 - F3 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
- F13 The option vests in four equal annual installments beginning on February 23, 2024.
| Open filing 0001539215-26-000014 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | Bhatt Padmanabh P. Officer: Sr. VP of IP, CSO | J Other acquisition or disposition (describe transaction) Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock (15,000) — exercise price 27.94 | Disposed (D) | 15,000 | 0 | — | 0 | Direct (D) | No | F3, F14 - F3 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
- F14 The option vests in four equal annual installments beginning on February 22, 2025.
| Open filing 0001539215-26-000014 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | Bhatt Padmanabh P. Officer: Sr. VP of IP, CSO | J Other acquisition or disposition (describe transaction) Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock (20,000) — exercise price 33.52 | Disposed (D) | 20,000 | 0 | — | 0 | Direct (D) | No | F3, F15 - F3 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
- F15 The option vests in four equal annual installments beginning on February 19, 2026.
| Open filing 0001539215-26-000014 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | Bhatt Padmanabh P. Officer: Sr. VP of IP, CSO | J Other acquisition or disposition (describe transaction) Derivative security: Employee Stock Option (Right to Buy) — underlying Common Stock (13,500) — exercise price 50.20 | Disposed (D) | 13,500 | 0 | — | 0 | Direct (D) | No | F3, F16 - F3 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
- F16 The option vests in four equal annual installments beginning on February 18, 2027.
| Open filing 0001539215-26-000014 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | Khattar Jack A. Director · Officer: President, CEO | J Other acquisition or disposition (describe transaction) Common Stock | Disposed (D) | 1,258,351 | 0 | — | 0 | Direct (D) | No | F1 - F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/26, Artemis Merger Sub Inc. merged with and into Supernus Pharmaceuticals, with Supernus Pharmaceuticals surviving as a wholly-owned subsidiary of Indivior. At the effective time, each outstanding share of Supernus Pharmaceuticals common stock was cancelled and automatically converted into the right to receive 1.5401 shares of Indivior common stock. In connection with the merger, Indivior changed its name to Supernus, Inc. The reporting person's shares of Supernus Pharmaceuticals common stock were disposed of, and the shares of Supernus, Inc. common stock received in exchange were acquired, pursuant to the merger. The reporting person received no cash consideration other than cash in lieu of a fractional share.
| Open filing 0001539937-26-000016 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | Khattar Jack A. Director · Officer: President, CEO | J Other acquisition or disposition (describe transaction) Common Stock | Disposed (D) | 958,100 | 0 | — | 0 | Indirect (I) By the KBT Trust | No | F1 - F1 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/26, Artemis Merger Sub Inc. merged with and into Supernus Pharmaceuticals, with Supernus Pharmaceuticals surviving as a wholly-owned subsidiary of Indivior. At the effective time, each outstanding share of Supernus Pharmaceuticals common stock was cancelled and automatically converted into the right to receive 1.5401 shares of Indivior common stock. In connection with the merger, Indivior changed its name to Supernus, Inc. The reporting person's shares of Supernus Pharmaceuticals common stock were disposed of, and the shares of Supernus, Inc. common stock received in exchange were acquired, pursuant to the merger. The reporting person received no cash consideration other than cash in lieu of a fractional share.
| Open filing 0001539937-26-000016 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | Khattar Jack A. Director · Officer: President, CEO | J Other acquisition or disposition (describe transaction) Derivative security: Restricted Stock Unit — underlying Common Stock (400,000) — exercise price 0 | Disposed (D) | 400,000 | 0 | — | 0 | Direct (D) | No | F2, F3 - F2 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
- F3 These restricted stock units (RSUs) are settled in common stock upon vesting, which occurs in four installments. 50% of the RSUs vest upon the closing of the merger-of-equals transaction between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. (the Closing). 15% of the RSUs vest upon the one-year anniversary of the Closing. 15% of the RSUs vest upon the two-year anniversary of the Closing. 20% of the RSUs vest upon the three-year anniversary of the Closing.
| Open filing 0001539937-26-000016 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-04 | Khattar Jack A. Director · Officer: President, CEO | J Other acquisition or disposition (describe transaction) Derivative security: Performance Share Unit — underlying Common Stock (19,320) | Disposed (D) | 19,320 | 0 | — | 0 | Direct (D) | No | F4, F2, F5 - F4 Each performance share unit represents the right to receive one share of Supernus common stock upon vesting.
- F2 Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. (Indivior), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. (Supernus Pharmaceuticals), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.
- F5 On February 22, 2024, the Reporting Person was awarded Performance Share Units with individual performance objectives and a defined performance period established on June 24, 2024.
| Open filing 0001539937-26-000016 Read from the filing’s XML Dispute this row |